Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | AFFIRM-AL: birtamimab vs placebo in patients with Mayo Stage IV AL amyloidosis

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, outlines the rationale of AFFIRM-AL (NCT04973137), a Phase III trial evaluating the efficacy and safety of birtamimab plus standard of care (SOC) compared to placebo plus SOC in patients with Mayo Stage IV AL amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Disclosures

Honoraria: Celgene, Med Learning Group, Research to Practice, Prothena, Apellis Pharmaceuticals, Amgen, AbbVie, Akcea Therapeutics, Sanofi, Telix Pharmaceuticals, Janssen Oncology, Juno/Celgene
Consulting or Advisory Role: Prothena, Bristol Myers Squibb/Sanofi
Travel, Accommodations, Expenses: Prothena, Celgene, Novartis